Pathogenetic insights from the treatment of rheumatoid arthritis

[1]  G. Schett,et al.  Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis. , 2017, Seminars in arthritis and rheumatism.

[2]  P. Tak,et al.  Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study , 2017, The Lancet.

[3]  J. Kremer,et al.  A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[4]  H. Mischak,et al.  Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups , 2017, Scientific Reports.

[5]  G. Schett.  Autoimmunity as a trigger for structural bone damage in rheumatoid arthritis , 2017, Modern rheumatology.

[6]  Kutty Selva Nandakumar,et al.  Regulation of autoantibody activity by the IL-23–TH17 axis determines the onset of autoimmune disease , 2016, Nature Immunology.

[7]  P. Tak,et al.  Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes , 2016, Annals of the rheumatic diseases.

[8]  H. Lorenz,et al.  Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs , 2016, Annals of the rheumatic diseases.

[9]  S. Marsal,et al.  Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial , 2016, Annals of the rheumatic diseases.

[10]  J. Isaacs,et al.  Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis , 2016, Annals of the rheumatic diseases.

[11]  J. Smolen,et al.  A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate , 2015, Annals of the rheumatic diseases.

[12]  P. Tak,et al.  Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases , 2016, Nature Reviews Drug Discovery.

[13]  M. Konig,et al.  Aggregatibacter actinomycetemcomitans–induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis , 2016, Science Translational Medicine.

[14]  E. Tan,et al.  Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor , 2016, The Journal of experimental medicine.

[15]  Khagendra Dahal,et al.  Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials , 2016, Rheumatology International.

[16]  J. Smolen,et al.  Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. , 2016, Rheumatology.

[17]  J. D. Clark,et al.  The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. , 2016, Clinical and experimental rheumatology.

[18]  A. Moore,et al.  Expanding antigen-specific regulatory networks to treat autoimmunity , 2016, Nature.

[19]  M. Cutolo,et al.  CTLA-4 blockade in the treatment of rheumatoid arthritis: an update , 2016, Expert review of clinical immunology.

[20]  L. Klareskog,et al.  Mechanisms involved in triggering rheumatoid arthritis , 2016, Immunological reviews.

[21]  I. McInnes,et al.  Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[22]  L. Klareskog,et al.  Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss , 2015, Annals of the rheumatic diseases.

[23]  H. Genant,et al.  Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II , 2015, Annals of the rheumatic diseases.

[24]  Rui-Ru Ji,et al.  Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen‐Presenting Cells , 2015, Arthritis & rheumatology.

[25]  J. Norris,et al.  Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment , 2015, Rheumatology.

[26]  P. Tak,et al.  The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts , 2014, Annals of the rheumatic diseases.

[27]  John D. Isaacs,et al.  Cytokines in rheumatoid arthritis — shaping the immunological landscape , 2016, Nature Reviews Rheumatology.

[28]  Ahmed M. Mehdi,et al.  Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients , 2015, Science Translational Medicine.

[29]  J. Kremer,et al.  Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis: A Consortium of Rheumatology Researchers of North America Registry Study , 2015, Arthritis & rheumatology.

[30]  J. Caamaño,et al.  Stromal cells in chronic inflammation and tertiary lymphoid organ formation. , 2015, Annual review of immunology.

[31]  H. L. Wright,et al.  Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab. , 2015, Rheumatology.

[32]  M. Milad,et al.  Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib†, ‡ , 2015, Arthritis & rheumatology.

[33]  David M. Wilson,et al.  Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation , 2015, Nature chemical biology.

[34]  I. McInnes,et al.  Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study , 2013, Annals of the rheumatic diseases.

[35]  G. Firestein,et al.  The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[36]  Gustavo Leon,et al.  Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study , 2014, Arthritis & rheumatology.

[37]  O. Ohara,et al.  Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome‐Wide DNA Microarray , 2014, Arthritis & rheumatology.

[38]  M. Rauh,et al.  T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway , 2014, Science Translational Medicine.

[39]  P. Emery,et al.  Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy , 2014, Annals of the rheumatic diseases.

[40]  F. Houssiau,et al.  Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium , 2014, Arthritis & rheumatology.

[41]  Jun S. Liu,et al.  Genetics of rheumatoid arthritis contributes to biology and drug discovery , 2013 .

[42]  J. Zwerina,et al.  Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis , 2013, Annals of the rheumatic diseases.

[43]  K. Engelke,et al.  Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies , 2013, Annals of the rheumatic diseases.

[44]  C. Huttenhower,et al.  Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis , 2013, eLife.

[45]  M. Dougados,et al.  CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. , 2013, Arthritis and rheumatism.

[46]  I. McInnes,et al.  Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm , 2013, Nature Reviews Rheumatology.

[47]  M. Fitzpatrick,et al.  Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis , 2013, Arthritis and rheumatism.

[48]  A. Wolk,et al.  Cigarette smoking and smoking cessation in relation to risk of rheumatoid arthritis in women , 2013, Arthritis Research & Therapy.

[49]  G. Hallmans,et al.  Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. , 2013, Arthritis and rheumatism.

[50]  J. Smolen,et al.  Forget personalised medicine and focus on abating disease activity , 2012, Annals of the rheumatic diseases.

[51]  N. Bottini,et al.  Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors , 2013, Nature Reviews Rheumatology.

[52]  S. Gay,et al.  Epigenetic contributions in the development of rheumatoid arthritis , 2012, Arthritis Research & Therapy.

[53]  Georg Schett,et al.  Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment , 2012, Nature Reviews Rheumatology.

[54]  J. Gallacher,et al.  C-reactive protein, fibrinogen, and cardiovascular disease prediction. , 2012, The New England journal of medicine.

[55]  Yoshiya Tanaka,et al.  The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. , 2012, Arthritis and rheumatism.

[56]  S. Kummerfeld,et al.  Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab , 2012, Annals of the rheumatic diseases.

[57]  R. Toes,et al.  Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. , 2012, The Journal of clinical investigation.

[58]  J. Kremer,et al.  Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial. , 2012, Arthritis and rheumatism.

[59]  G. Firestein,et al.  The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon , 2011, Annals of the rheumatic diseases.

[60]  P. V. van Riel,et al.  Abatacept modulates proinflammatory macrophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation , 2011, Annals of the rheumatic diseases.

[61]  K. Kanbe,et al.  Immunohistological analysis of synovium treated with abatacept in rheumatoid arthritis , 2013, Rheumatology International.

[62]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[63]  D. Mozaffarian,et al.  Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. , 2011, The American journal of cardiology.

[64]  R. V. van Vollenhoven,et al.  Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. , 2011, Arthritis and rheumatism.

[65]  P. V. van Riel,et al.  Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries , 2011, Annals of the rheumatic diseases.

[66]  C. Galant,et al.  Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium. , 2011, Arthritis and rheumatism.

[67]  K. Kalunian,et al.  CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. , 2011, Rheumatology.

[68]  C. Wijbrandts,et al.  Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab , 2011, Annals of the rheumatic diseases.

[69]  S. Douglas,et al.  Immune suppression and immune activation in depression , 2011, Brain, Behavior, and Immunity.

[70]  George Kollias,et al.  Blockade of TNF-α rapidly inhibits pain responses in the central nervous system , 2011, Proceedings of the National Academy of Sciences.

[71]  L. Alfredsson,et al.  Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke , 2010, Annals of the rheumatic diseases.

[72]  M. Hochberg,et al.  Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[73]  Brandon J. Bravo,et al.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. , 2011, Nature chemical biology.

[74]  J. Lundeberg,et al.  The Gene Expression Profile in the Synovium as a Predictor of the Clinical Response to Infliximab Treatment in Rheumatoid Arthritis , 2010, PloS one.

[75]  S. Pimlott,et al.  Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study , 2010, Annals of the rheumatic diseases.

[76]  L. Trinquart,et al.  High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. , 2010, Archives of cardiovascular diseases.

[77]  P. Tak,et al.  Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis , 2009, Annals of the rheumatic diseases.

[78]  J. Pablos,et al.  Immature Blood Vessels in Rheumatoid Synovium Are Selectively Depleted in Response to Anti-TNF Therapy , 2009, PloS one.

[79]  C. Wijbrandts,et al.  The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. , 2009, Arthritis and rheumatism.

[80]  B. Bresnihan,et al.  Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers , 2009, The Journal of Rheumatology.

[81]  A. Radjenovic,et al.  Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study , 2008, Annals of the rheumatic diseases.

[82]  T. Huizinga,et al.  Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation , 2008, Annals of the rheumatic diseases.

[83]  S. Marsal,et al.  Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor α therapy in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[84]  J. Zwerina,et al.  How antirheumatic drugs protect joints from damage in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[85]  P. Emery,et al.  The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). , 2008, Rheumatology.

[86]  K. Kalunian,et al.  Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab , 2008, Arthritis research & therapy.

[87]  B. Bresnihan,et al.  Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. , 2008, Clinical and experimental rheumatology.

[88]  F. Lund.  Cytokine-producing B lymphocytes-key regulators of immunity. , 2008, Current opinion in immunology.

[89]  P. Tak,et al.  Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. , 2008, Best practice & research. Clinical rheumatology.

[90]  K. Kalunian,et al.  Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results , 2007, Annals of the rheumatic diseases.

[91]  D. van Schaardenburg,et al.  Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[92]  E. Pérez-Pampín,et al.  All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists , 2007, Annals of the rheumatic diseases.

[93]  J. Dayer,et al.  Is IL-1 a good therapeutic target in the treatment of arthritis? , 2006, Best practice & research. Clinical rheumatology.

[94]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[95]  D. Patel,et al.  Cadherin-11 Provides Specific Cellular Adhesion between Fibroblast-like Synoviocytes , 2004, The Journal of experimental medicine.

[96]  S. Yamasaki,et al.  Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. , 2003, Genes & development.

[97]  Göran Hallmans,et al.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[98]  R. Fanin,et al.  Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. , 2002, Arthritis and rheumatism.

[99]  F. Breedveld,et al.  Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.

[100]  F. Breedveld,et al.  Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. , 1996, Arthritis and rheumatism.